Canaccord Genuity Lowers PT & Estimates on ArthroCare (ARTC); DoJ Overhang Remains

February 17, 2012 10:34 AM EST
Get Alerts ARTC Hot Sheet
Price: $9.97 --0%

Rating Summary:
    3 Buy, 6 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 8 | Down: 6 | New: 26
Join SI Premium – FREE
Canaccord Genuity maintains a 'Buy' on ArthroCare (NASDAQ: ARTC) price target slashed from $43.50 to $29.

Analyst, William J. Plovanic, said, "We maintain our rating post a weak Q4/11 and disappointing 2012 guidance. We believe a new DoJ investigation could extend the timeline for the company’s legal overhang by another 12–24 months. As a result, we believe shareholders that have been waiting for clearance of legal issues may lose patience in the name. Alternatively, at ~$30 per share, we note that the company has a free cash flow yield of ~10%, which is the highest of any of our coverage companies."

Canaccord cuts FY12 EPS estimate from $1.70 to $1.33.

For an analyst ratings summary and ratings history on ArthroCare click here. For more ratings news on ArthroCare click here.

Shares of ArthroCare closed at $30.77 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change